George Paletta, Jr. Joins Longeveron Board
MIAMI, Oct. 01, 2025 – Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology firm dedicated to developing cellular therapies for critical, rare, and aging-related conditions, proudly announces the election of Dr. George Paletta, Jr., MD, MBA, to its Board of Directors. Dr. Paletta is a highly respected orthopedic surgeon known for his role as the primary physician for the St. Louis Cardinals, and has a track record of innovation in the medical field. He has been instrumental in the development of ambulatory surgical centers (ASCs), having successfully executed the sales of two centers totaling close to $1 billion.
Importance of Dr. Paletta's Experience
“We're thrilled to welcome George to our Board,” noted Joshua Hare, Co-founder and Chief Science Officer of Longeveron. “His extensive experience as a physician and entrepreneur is invaluable. This expertise will significantly contribute as Longeveron advances its stem cell therapies aimed at the most vulnerable groups, including children and the elderly. Our actively growing pipeline, including a critical clinical trial in hypoplastic left heart syndrome (HLHS), marks an exciting time for Longeveron.”
A Vision for Stem Cell Therapy
Dr. Paletta expressed his enthusiasm for joining Longeveron at a pivotal moment for the company, highlighting the advancements in stem cell research since its inception. “Stem cell therapy represents a transformative potential for treating patients suffering from rare pediatric conditions and chronic illnesses related to aging. I see enormous opportunities for Longeveron to lead the way in delivering these therapies to the market, improving healthcare access and outcomes for many,” he stated.
Dr. Paletta's Academic and Professional Background
Holding both an MBA and a medical degree, Dr. Paletta is a well-rounded candidate for Longeveron’s Board. He received his Bachelor of Arts in Chemistry from the College of Holy Cross and earned his MD from the renowned Johns Hopkins University School of Medicine. He completed his orthopedic residency at the prestigious Hospital for Special Surgery in New York City and pursued post-graduate fellowships at recognized institutions including The Cleveland Clinic and Children’s Hospital of Michigan. His professional journey spans both academic and private practice settings at various esteemed institutions, along with extensive involvement in medical device innovation.
About Longeveron Inc.
Longeveron is at the forefront of clinical biotechnology, focusing on regenerative medicines to tackle significant unmet medical needs. The cornerstone of their product line is laromestrocel (Lomecel-B™), a unique therapy derived from the mesenchymal stem cells sourced from young, healthy adults. This therapy boasts a range of potential action mechanisms, offering promise in enhancing vascular function, regeneration, and reducing inflammation across multiple disease categories.
Pipeline and Future Directions
Longeveron is actively pursuing four critical indications in their development pipeline, which includes hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, pediatric dilated cardiomyopathy (DCM), and issues related to aging frailty. Their development programs have received key FDA designations that recognize their potential benefit for patients, including orphan drug status and regenerative medicine advanced therapy (RMAT) status.
Connect with Longeveron
To learn more about Longeveron’s innovative initiatives and breakthroughs in regenerative medicine, please visit their official website or engage with them across social media platforms.
Frequently Asked Questions
What is the main focus of Longeveron Inc.?
Longeveron focuses on developing cellular therapies for critical rare pediatric and aging-related health conditions.
Who is George Paletta, Jr.?
George Paletta, Jr. is an orthopedic surgeon and entrepreneur, now serving on the Longeveron Board of Directors.
What notable achievements does Dr. Paletta have?
Dr. Paletta has developed and successfully sold ambulatory surgical centers valued at nearly $1 billion and holds various patents.
What is laromestrocel?
Laromestrocel is Longeveron's lead investigational product, which utilizes mesenchymal stem cells for therapeutic purposes.
What are the future directions for Longeveron?
Longeveron aims to expand its stem cell therapy pipeline, targeting vital health conditions with significant FDA designations.
